Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 8:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,544 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Girls, alone Clear all
Completed Not applicable Interventional Results available

Web-Based Treatment of Heavy Drinking Among Women With a History of Sexual Trauma

NCT03111056
View directory record Official record
Conditions
Sexual Assault, Heavy Drinking
Interventions
Alc-ERDT
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 25, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants

NCT06342700
View directory record Official record
Conditions
Autoimmune Disorder, Healthy Volunteers
Interventions
Rilzabrutinib crystalline form, Rilzabrutinib amorphous form
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 25, 2026, 8:03 PM EDT
Completed Phase 3 Interventional Results available

Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.

NCT00500539
View directory record Official record
Conditions
Asthma
Interventions
omalizumab
Drug
Lead sponsor
Novartis
Industry
Eligibility
12 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
26
States / cities
Scottsdale, Arizona • Palmdale, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2011 · Synced Oct 25, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate and Compare the Bioequivalence of Two Abaloparatide-sMTS Treatments in Healthy Women.

NCT04936984
View directory record Official record
Conditions
Osteoporosis
Interventions
abaloparatide-sMTS (Patheon), abaloparatide-sMTS (Kindeva)
Combination Product
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 25, 2026, 8:03 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Black Girls Move Physical Activity and Improving Dietary Intake Among Black Adolescent Daughters

NCT05433415
View directory record Official record
Conditions
Adolescent Obesity, Diabetes Mellitus
Interventions
Black Girls Move
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 25, 2026, 8:03 PM EDT
Terminated Not applicable Interventional

Vesair Balloon Confirmatory Trial (VECTOR)

NCT03794206
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
Vesair Balloon
Device
Lead sponsor
Solace Therapeutics, Inc.
Industry
Eligibility
Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
8
States / cities
Arlington Heights, Illinois • Shreveport, Louisiana • Hanover, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Oct 25, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect Study of D-0502 Tablet in Healthy Volunteers

NCT03810625
View directory record Official record
Conditions
Breast Cancer
Interventions
D-0502
Drug
Lead sponsor
InventisBio Co., Ltd
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 25, 2026, 8:03 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

The Use of Functional Confections in Promoting Oral Health

NCT01514552
View directory record Official record
Conditions
Oral Health, Oral Cancer, Gum Disease
Interventions
Strawberry gummy, Placebo control gummy
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 25, 2026, 8:03 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Trans-Abdominal Fetal Pulse Oximetry - EFS-IDE

NCT06405984
View directory record Official record
Conditions
Fetal Hypoxia, Fetal Distress, Fetal Conditions, Fetal Complications, Labor Fetal Anoxia, Labor (Obstetrics)--Complications, Oxygen Deficiency
Interventions
Fetal Oxygenation Measurements
Device
Lead sponsor
Raydiant Oximetry, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 25, 2026, 8:03 PM EDT
Completed Phase 1 Interventional

A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Therapeutically

NCT02220348
View directory record Official record
Conditions
Breast Feeding, Constipation, Irritable Bowel Syndrome
Interventions
linaclotide
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Iowa City, Iowa • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 25, 2026, 8:03 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Testing Feasibility of Care Coordination and Motivational Interviewing for Women With a Recent Preterm Birth

NCT05120843
View directory record Official record
Conditions
Preterm Birth, Health Care Utilization, Tobacco Use, Contraceptive Usage, Depression, Weight, Birth
Interventions
Care coordination and motivational interviewing
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
14 Years to 45 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 25, 2026, 8:03 PM EDT
Terminated Not applicable Interventional Results available

Cap Assisted Upper Endoscopy Versus High Definition White Light Endoscopy and Narrow Band Imaging Alone In The Detection Of Visible Lesions Barrett's Esophagus: A Randomized Tandem Study

NCT03417570
View directory record Official record
Conditions
Barrett Esophagus
Interventions
Esophagogastroduodenoscopy with high definition-white light end endoscopy (HD-WLE) and narrow band imaging (NBI), Olympus Disposable Distal Attachment Cap
Procedure · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 25, 2026, 8:03 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

NCT02502266
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Cediranib, Cediranib Maleate, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Questionnaire Administration, Topotecan, Topotecan Hydrochloride
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
370
States / cities
Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 285 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 25, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects

NCT04242953
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
SCO-120, matching placebo
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years to 99 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Dilworth, Minnesota • Creve Coeur, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 25, 2026, 8:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of a Female Hormone Balance Supplement on Symptoms of Polycystic Ovary Syndrome and Severe Premenstrual Syndrome

NCT06124300
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Premenstrual Syndrome
Interventions
Female Hormone Balance Supplement
Dietary Supplement
Lead sponsor
Rael
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 25, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women

NCT04283656
View directory record Official record
Conditions
Transgender Health, Gender Dysphoria, Transgender Women, Human Immunodeficiency Virus
Interventions
Doravirine/Lamivudine/Tenofovir, Spironolactone 100mg, Estradiol 2mg, Placebo
Drug · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 25, 2026, 8:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Journey to Better Health

NCT02938312
View directory record Official record
Conditions
Weight Loss
Interventions
Weight Loss Only, Weight Loss Plus
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
30 Years to 70 Years · Female only
Enrollment
409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Oct 25, 2026, 8:03 PM EDT
Completed Phase 3 Interventional Results available

Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis

NCT02022007
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Disorder of Glucose Regulation
Interventions
Metformin XR, Saxagliptin, Saxagliptin-Metformin XR
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 25, 2026, 8:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Testing Adaptive Interventions to Improve Physical Activity for Sedentary Women

NCT03558828
View directory record Official record
Conditions
Physical Activity
Interventions
Step 1: PA Monitor, Step 1: PA Monitor + Text, Step 2: PA Monitor with Calls, Step 2: PA Monitor with Meetings, Step 2: PA Monitor + Texts with Calls, Step 2: PA Monitor + Texts with Meetings, Step 3: PA Monitor
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 25, 2026, 8:03 PM EDT
Withdrawn No phase listed Observational

A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn Capsules With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)

NCT06058728
View directory record Official record
Conditions
Uterine Fibroids (UF)
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 25, 2026, 8:03 PM EDT
Not yet recruiting Phase 2 Interventional

Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

NCT06732245
View directory record Official record
Conditions
Obesity and Overweight
Interventions
NA-931, Tirzepatide, NA-931 150 mg + no Tirzepatide
Drug
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
19 Years to 80 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 25, 2026, 8:03 PM EDT
Completed Phase 2 Interventional

A Study of NOE-115 in Women With Vasomotor Symptoms Due to Menopause

NCT06385795
View directory record Official record
Conditions
Menopause Syndrome, Menopause, Hot Flashes
Interventions
NOE-115
Drug
Lead sponsor
Noema Pharma AG
Industry
Eligibility
45 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
San Diego, California • Jacksonville, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 25, 2026, 8:03 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Influences of Long-acting Reversible Contraceptives on Iron Status and Physiological Responses to Extreme Environments in Women

NCT06909695
View directory record Official record
Conditions
Contraception, Iron Deficiencies
Interventions
Blood volume and environmental testing
Other
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years to 40 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 25, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy Adults

NCT00741273
View directory record Official record
Conditions
Impaired Liver Function
Interventions
Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 62 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Oct 25, 2026, 8:03 PM EDT